1.Hughes RA., Cornblath DR. Guillain-Barré syndrome. Lancet. 2005. 366:1653–1666.
Article
2.Rudnicki SA., Dalmau J. Paraneoplastic syndromes of the peripheral nerves. Curr Opin Neurol. 2005. 18:598–603.
Article
3.Graus F., Delattre J., Antoine J., Dalmau J., Giometto B., Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004. 75:1135–1140.
Article
4.ViglianiM-C. Magistrello M., Polo P., Mutani R., Chiò A. Risk of cancer in patients with Guillain-Barre syndrome (GBS). J Neurol. 2004. 251:321–326.
5.Cicero G., Fulfaro F., Caraceni A., Arcara C., Badalamenti G., Intrivici C, et al. A case of guillain-barre syndrome in a patient with non small cell lung cancer treated with chemotherapy. J Chemother. 2006. 18:325–327.
6.Navani V., Webster D., Williams SK., Agranoff D. Guillain-Barré syndrome as a paraneoplastic manifestation of disseminated squamous cell carcinoma. BMJ Case Rep. 2013. 2013:pii: bcr2013 009700.
7.Naveed S., Okoli K., Hollingsworth J., Kasmani R. Guillain-Barre syndrome as a paraneoplastic manifestation of small-cell carcinoma of lung. South Med J. 2010. 103:156–158.
8.Windebank AJ., Grisold W. Chemotherapy–induced neuropathy. J Peripher Nerv Syst. 2008. 13:27–46.
Article
9.Kusunoki S., Hitoshi S., Kaida KI., Arita M., Kanazawa I. Mono-specific anti–GD1b IgG is required to induce rabbit ataxic neuropathy. Ann Neurol. 1999. 45:400–403.
Article
10.Miyazaki T., Kusunoki S., Kaida K., Shiina M., Kanazawa I. Guillain-Barré syndrome associated with IgG monospecific to ganglioside GD1b. Neurology. 2001. 56:1227–1229.
Article